DOCSLIB.ORG

Low-Grade Central Nervous System Tumors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Low-Grade Central Nervous System Tumors Neurosurg Focus 12 (2):Article 1, 2002, Click here to return to Table of Contents Low-grade central nervous system tumors M. BEATRIZ S. LOPES, M.D., AND EDWARD R. LAWS, JR., M.D. Departments of Pathology (Neuropathology) and Neurological Surgery, University of Virginia Health Sciences Center, Charlottesville, Virginia Low-grade tumors of the central nervous system constitute 15 to 35% of primary brain tumors. Although this cate- gory of tumors encompasses a number of different well-characterized entities, low-grade tumors constitute every tumor not obviously malignant at initial diagnosis. In this brief review, the authors discuss the pathological classification, diagnostic procedures, treatment, and possible pathogenic mechanisms of these tumors. Emphasis is given in the neu- roradiological and pathological features of the several entities. KEY WORDS • glioma • astrocytoma • treatment outcome Low-grade gliomas of the brain represent a large pro- toses. The pilocytic (juvenile) astrocytoma is a character- portion of primary brain tumors, ranging from 15 to 35% istic, more circumscribed lesion occurring primarily in in most reported series.1–5 They include a remarkable di- childhood and with a predilection for being located in the versity of lesions, all of which have been lumped together cerebellum. It usually appears as a cystic tumor with a under the heading of "low-grade glioma." This category mural nodule. The tumor tissue itself may have features of includes virtually every tumor of glial origin that is not microcystic degeneration and Rosenthal fibers which are overtly malignant at the time of initial diagnosis. degenerative structures in the astrocytic processes. Other reasonably common types of low-grade gliomas include CLASSIFICATION OF GLIOMAS the low-grade oligodendroglioma and the low-grade ependymoma, which is usually anatomically related to the Table 1 provides a classification of low-grade tumors of ventricular ependymal lining. the central nervous system. The most common low-grade There is a large variety of uncommon tumors also cate- glioma is the ordinary astrocytoma. Once divided into fib- gorized as low-grade gliomas. The optic nerve glioma is rillary and protoplasmic subtypes, this lesion currently is very frequently found in the context of NF Type 1. It can thought to be derived from ordinary astrocytes, and it usu- occur as an "anterior" lesion that affects one or both optic ally occurs as a relatively homogeneous but infiltrative le- nerves, primarily evolving in the optic nerve sheath, or a sion. Closely related is the mixed glioma (mixed oligoas- "posterior" lesion that involves the optic chiasm and occa- trocytoma) that consists of both astrocytoma cells and sionally the hypothalamus. In approximately 40% of pa- oligodendroglioma phenotypes in varying proportions. tients harboring these lesions evidence of NF Type 1 is The subcategory "low-grade" tends to exclude those le- observed.2 sions with features of a high degree of pleomorphism, Another genetically related low-grade glioma is the necrosis, or vascular proliferation, or large numbers of mi- subependymal giant cell astrocytoma associated with tu- berous sclerosis. The characteristic location as well as its Abbreviations used in this paper: CT = computerized tomo- association with giant cells help define this lesion. There graphy; EEG = electroencephalogram; GFAP = glial fibrillary acid- are some indolent tumors categorized as low-grade glio- ic protein; MR = magnetic resonance; NF = neurofibromatosis; mas that commonly present with seizures. They include SEGA = subependymal giant cell astrocytoma; WHO = World two mixed neuronal–glial tumors: the ganglioglioma, Health Organization. which may also be cystic and partially calcified, and the Neurosurg. Focus / Volume 12 / February, 2002 1 Unauthenticated | Downloaded 09/29/21 11:11 AM UTC M. B. S. Lopes and E. R. Laws, Jr. TABLE 1 TABLE 2 Classification of low-grade tumors of the central nervous system Modalities used in the diagnosis of glioma gliomas neurological exam: papilledema, localizing signs astrocytoma (astrocytoma WHO Grade II; low-grade astrocytoma, EEG: focal changes, delta activity, epileptiform discharges ordinary astrocytoma) CT scan & MR imaging oligodendroglioma (oligodendroglioma WHO Grade II; low-grade angiography (when indicated) oligodendroglioma) lumbar puncture (generally not indicated) mixed oligoastrocytoma (mixed oligoastrocytoma WHO Grade II; low-grade mixed glioma) pilocytic astrocytoma (juvenile pilocytic astrocytoma; WHO Grade I) optic nerve glioma pleomorphic xanthoastrocytoma (WHO Grade II) DIAGNOSTIC PROCEDURES FOR LOW-GRADE subependymal giant cell astrocytoma (WHO Grade I) GLIOMAS ependymoma (variants: cellular, papillary, clear cell) myxopapillary ependymoma A summary of diagnostic procedures is provided in subependymoma Table 2. In patients presenting with seizure disorders, choroid plexus papilloma EEG can be used to diagnose the disease. The characteris- neuronal & mixed glial–neuronal tumors gangliocytoma tic EEG appearance of a low-grade glioma includes slow central neurocytoma or delta waves as well as any associated epileptiform ganglioglioma activity. Currently the most commonly used diagnostic dysembryoplastic neuroepithelial tumor modality is the imaging study, usually MR imaging, desmoplastic infantile ganglioglioma which provides exquisite detail both of the anatomy of the lesion and often of its pathophysiology (Tables 3 and 4). A stereotactic biopsy sampling procedure is commonly performed in attempts to diagnose presumed low-grade dysembryoplastic neuroepithelial tumor, which is usually gliomas detected by imaging studies. These biopsy proce- located in the temporal lobe. The pleomorphic xanthoas- dures are usually effective; however, because the patho- trocytoma is a characteristic superficial tumor also associ- logical findings are occasionally equivocal, one must al- ated with seizures. These lesions ordinarily have quite a ways be concerned with a sampling error in tumors that low proliferative activity and often can be controlled by contain areas of differing degrees of malignancy. treatment with radical but subtotal resection alone. The central neurocytoma is a peculiar and uncommon TREATMENT OF LOW-GRADE GLIOMAS tumor, likely of neuronal derivation. These tumors are fre- quently associated with the third ventricle and also have In a significant proportion of detected low-grade glio- an indolent course. mas the patients may be appropriate candidates for con- Some investigators classify choroid plexus papillomas servative management. Patients harboring these lesions together with the gliomas. These tumors arise from the can be treated with anticonvulsant medication and re- choroid plexus, either in the lateral ventricles, the third peated neurodiagnostic imaging studies, withholding in- ventricle, or the fourth ventricle, and frequently present as tervention until there has been a change either clinically or obstructive masses. radiologically. Partial resection may be appropriate for some low-grade astrocytomas, particularly those that are near important areas of the brain. Partial resection can CLINICAL FEATURES OF LOW-GRADE result in long-term favorable results in patients with pilo- GLIOMAS cytic astrocytomas, dysembryoplastic neuroepithelial tu- It is clear that the location of the lesion tends to be the mors, and some gangliogliomas and pleomorphic xantho- most important factor in determining the nature of the astrocytomas. symptoms and signs. Because these lesions are usually Radical or total resection is the surgical procedure of slow growing, seizures may be the presenting clinical choice for all forms of glioma, because in many of the symptom and may precede the diagnosis by many years. Seizures are particularly likely to occur in cases in which the lesions involve the temporal and the frontal lobes. TABLE 3 Visual symptoms are relatively common in low-grade Magnetic resonance imaging features of low-grade astrocytoma gliomas, depending on the actual location of the tumor, and its involvement of the optic apparatus or optic pathways. pathological features detectable cysts In cases of slowly progressive lesions that expand to necrosis affect important areas of the brain, the patients may pre- hemorrhage sent with progressive neurological deficits such as hemi- edema paresis, sensory changes, or difficulty with speech and blood–brain barrier disruption language. lesion analysis In cases in which lesions occlude or obstruct the ce- circumscribed compared w/ infiltrative unifocal compared w/ multifocal or diffuse rebrospinal fluid pathways, the patients may present with “benign” compared w/ “malignant” progressive signs of increased intracranial pressure. 2 Neurosurg. Focus / Volume 12 / February, 2002 Unauthenticated | Downloaded 09/29/21 11:11 AM UTC Low-grade CNS tumors TABLE 4 Magnetic resonance imaging features of various types of low-grade tumors MR Imaging Tumor Type T1-Weighted Gadolinium Enhancement low-grade astrocytoma hypointense none low-grade astrocytoma, optic nerve glioma isointense, expansive little or none & brainstem glioma low-grade oligoastrocytoma (infiltrative) hyperintense, homogeneous indistinct borders slight pilocytic astrocytoma hyperintense, well demarcated, cystic yes ganglioglioma cystic, isointense or hyper- yes intense borders anaplastic astrocytoma heterogeneous heterogeneous patients with these tumors complete removal of the lesion more recent laboratory work seems to support the concept can result
Load more

Recommended publications
  • Neurofibromatosis Type 2 (NF2)
    International Journal of Molecular Sciences Review Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis Suha Bachir 1,† , Sanjit Shah 2,† , Scott Shapiro 3,†, Abigail Koehler 4, Abdelkader Mahammedi 5 , Ravi N. Samy 3, Mario Zuccarello 2, Elizabeth Schorry 1 and Soma Sengupta 4,* 1 Department of Genetics, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA; [email protected] (S.B.); [email protected] (E.S.) 2 Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (M.Z.) 3 Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (R.N.S.) 4 Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] 5 Department of Radiology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression.
    [Show full text]
  • Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1
    [CANCER RESEARCH 49, 6137-6143. November 1, 1989] Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1 Susan Preston-Martin,2 Wendy Mack, and Brian E. Henderson Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033 ABSTRACT views with proxy respondents, we were unable to include a large proportion of otherwise eligible cases because they were deceased or Detailed job histories and information about other suspected risk were too ill or impaired to participate in an interview. The Los Angeles factors were obtained during interviews with 272 men aged 25-69 with a County Cancer Surveillance Program identified the cases (26). All primary brain tumor first diagnosed during 1980-1984 and with 272 diagnoses had been microscopically confirmed. individually matched neighbor controls. Separate analyses were con A total of 478 patients were identified. The hospital and attending ducted for the 202 glioma pairs and the 70 meningioma pairs. Meningi- physician granted us permission to contact 396 (83%) patients. We oma, but not glioma, was related to having a serious head injury 20 or were unable to locate 22 patients, 38 chose not to participate, and 60 more years before diagnosis (odds ratio (OR) = 2.3; 95% confidence were aphasie or too ill to complete the interview. We interviewed 277 interval (CI) = 1.1-5.4), and a clear dose-response effect was observed patients (74% of the 374 patients contacted about the study or 58% of relating meningioma risk to number of serious head injuries (/' for trend the initial 478 patients).
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • A Case of Intramedullary Spinal Cord Astrocytoma Associated with Neurofibromatosis Type 1
    KISEP J Korean Neurosurg Soc 36 : 69-71, 2004 Case Report A Case of Intramedullary Spinal Cord Astrocytoma Associated with Neurofibromatosis Type 1 Jae Taek Hong, M.D.,1 Sang Won Lee, M.D.,1 Byung Chul Son, M.D.,1 Moon Chan Kim, M.D.2 Department of Neurosurgery,1 St. Vincent Hospital, The Catholic University of Korea, Suwon, Korea Department of Neurosurgery,2 Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea The authors report a symptomatic intramedullary spinal cord astrocytoma in the thoracolumbar area associated with neurofibromatosis type 1 (NF-1). A 38-year-old woman presented with paraparesis. Magnetic resonance imaging revealed an intramedullary lesion within the lower thoracic spinal cord and conus medullaris, which was removed surgically. Pathological investigation showed anaplastic astrocytoma. This case confirms that the diagnosis criteria set by the National Institute of Health Consensus Development Conference can be useful to differentiate ependymoma from astrocytoma when making a preoperative diagnosis of intramedullary spinal cord tumor in patients of NF-1. KEY WORDS : Astrocytoma·Intramedullary cord tumor·Neurofibromatosis. Introduction eurofibromatosis type 1 (NF-1), also known as von N Recklinghausen's disease, is one of the most common autosomal dominant inherited disorders with an incidence of 1 in 3,000 individuals and is characterized by a predisposition to tumors of the nervous system5,6,12,16). Central nervous system lesions associated with NF-1 include optic nerve glioma and low-grade gliomas of the hypothalamus, cerebellum and brain stem6,10). Since the introduction of magnetic resonance(MR) imaging, Fig. 1. Photograph of the patient's back shows multiple subcutaneous incidental lesions with uncertain pathological characteristic nodules (black arrow) and a cafe-au-lait spot (white arrow), which have been a frequent finding in the brain and spinal cord of are typical of NF-1.
    [Show full text]
  • Pediatric Orbital Tumors and Lacrimal Drainage System
    Pediatric Orbital Tumors and Lacrimal Drainage System Peter MacIntosh, MD University of Illinois • No financial disclosures Dermoid Cyst • Congenital • Keratinized epidermis • Dermal appendage • Trapped during embryogenesis • 6% of lesions • 40-50% of orbital pediatric orbital lesion • Usually discovered in the first year of life • Painless/firm/subQ mass • Rarely presents as an acute inflammatory lesion (Rupture?) • Frontozygomatic (70%) • Maxillofrontal (20%) suture Imaging - CT • Erosion/remodeling of bone • Adjacent bony changes: “smooth fossa” (85%) • Dumbell dermoid: extraorbital and intraorbital components through bony defect Imaging - MRI • Encapsulated • Enhancement of wall but not lumen Treatment Options • Observation • Risk of anesthesia • Surgical Removal • Changes to bone • Rupture of cyst can lead to acute inflammation • Irrigation • Abx • Steroids Dermoid INFANTILE/Capillary Hemangioma • Common BENIGN orbital lesion of children • F>M • Prematurity • Appears in 1st or 2nd week of life • Soft, bluish mass deep to the eyelid • Superonasal orbit • Rapidly expands over 6-12 months • Increases with valsalva (crying) • Clinical findings • Proptosis Astigmatism • Strabismus Amblyopia INFANTILE/Capillary Hemangioma • May enlarge for 1-2 years then regress • 70-80% resolve before age 7 • HIGH flow on doppler • Kasabach-Merritt Syndrome • Multiple large visceral capillary hemangiomas • Sequestration of platelets into tumor • Consumptive thrombocytopenia • Supportive therapy and treat underlying tumor • Complications • DIC • death •Homogenous
    [Show full text]
  • Neuro-Oncology 1 XX(XX), 1–12, 2016 | Doi:10.1093/Neuonc/Now267
    Neuro-Oncology 1 XX(XX), 1–12, 2016 | doi:10.1093/neuonc/now267 Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction Joseph A. Toonen, Yu Ma, and David H. Gutmann Department of Neurology, Washington University School of Medicine (WUSM), St Louis, Missouri (J.A.T., Y.M., D.H.G.) Corresponding Author: David H. Gutmann, MD, PhD, Department of Neurology, Washington University, Box 8111, 660 S. Euclid Avenue, St. Louis MO 63110 ([email protected]). Abstract Background. Optic gliomas arising in the neurofibromatosis type 1 (NF1) cancer predisposition syndrome cause reduced visual acuity in 30%–50% of affected children. Since human specimens are rare, genetically engineered mouse (GEM) models have been successfully employed for preclinical therapeutic discovery and validation. However, the sequence of cellular and molecular events that culminate in retinal dysfunction and vision loss has not been fully defined relevant to potential neuroprotective treatment strategies. Methods. Nf1flox/mut GFAP-Cre (FMC) mice and age-matched Nf1flox/flox (FF) controls were euthanized at defined intervals from 2 weeks to 24 weeks of age. Optic nerve volumes were measured, and optic nerves/retinae analyzed by immunohistochemistry. Optical coherence tomography (OCT) was performed on anesthetized mice. FMC mice were treated with lovastatin from 12 to 16 weeks of age. Results. The earliest event in tumorigenesis was a persistent elevation in proliferation (4 wk), which preceded sustained microglia numbers and incremental increases in S100+ glial cells. Microglia activation, as evidenced by increased interleukin (IL)-1β expression and morphologic changes, coincided with axonal injury and retinal ganglion cell (RGC) apoptosis (6 wk).
    [Show full text]
  • Survival and Functional Outcome of Childhood Spinal Cord Low-Grade Gliomas
    J Neurosurg Pediatrics 4:000–000,254–261, 2009 Survival and functional outcome of childhood spinal cord low-grade gliomas Clinical article KATRIN SCHEINEMANN, M.D.,1 UTE BARTELS, M.D.,2 ANNIE HUANG, M.D., PH.D.,2 CYNTHIA HAWKINS, M.D., PH.D.,3 ABHAYA V. KULKARNI, M.D., PH.D.,4 ERIC BOUFFET, M.D.,2 AND URI TABORI, M.D.2 1Division of Hematology/Oncology, McMaster Children’s Hospital, Hamilton; and Divisions of 2Hematology/ Oncology, 3Pathology, and 4Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada Object. Intramedullary spinal cord low-grade gliomas (LGGs) are rare CNS neoplasms in pediatric patients, and there is little information on therapy for and outcome of these tumors in this population. Furthermore, most patient series combine adult and pediatric patients or high- and low-grade tumors, resulting in controversial data regarding optimal treatment of these children. To clarify these issues, the authors performed a regional population-based study of spinal cord LGGs in pediatric patients. Methods.$OOSHGLDWULFSDWLHQWVZLWK/**VWUHDWHGGXULQJWKH05LPDJLQJHUD ² ZHUHLGHQWLÀHGLQ the comprehensive database of the Hospital for Sick Children in Toronto. Data on demographics, pathology, treat- ment details, and outcomes were collected. Results. Spinal cord LGGs in pediatric patients constituted 29 (4.6%) of 635 LGGs. Epidemiological and clini- cal data in this cohort were different than in patients with other spinal tumors and strikingly similar to data from pediatric patients with intracranial LGGs. The authors observed an age peak at 2 years and a male predominance in patients with these tumors. Histological testing revealed a Grade I astrocytoma in 86% of tumors.
    [Show full text]
  • Clinical Manifestations of Hypothalamic Tumors*
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 6 Copyright © 1980, Institute for Clinical Science, Inc. Clinical Manifestations of Hypothalamic Tumors* ADOLFO D. GARNICA, M.D., MICHAEL L. NETZLOFF, M.D.,f and A. L. ROSENBLOOM, M.D. Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32610 and f Department of Human Development, Michigan State University East Lansing, MI 88823 ABSTRACT The regulatory function of the central nervous system encompasses di­ verse endocrine, metabolic, and behavioral processes. Many of these origi­ nate, are integrated, or are coordinated through hypothalamic pathways or nuclei. Thus, tumors affecting areas projecting to the hypothalamus, tumors of the hypothalamus, and tumors invading or compressing the hypothalamus can produce abnormalities of hypothalamic function. Introduction tary.4,7,31 A secretory function for certain hypothalamic neurons was postulated in Until recently, no endocrine disorder 1928 and subsequently confirmed by the directly attributable to hypothalamic dys­ demonstration of hormone synthesis in function had been recognized, and the the supraoptic and paraventricular nu­ majority of endocrine-metabolic homeo­ clei.28,53 Moreover, observations on the static processes were acknowledged to be effects of environment on the menstrual under the control of the anterior pitui­ cycles of women and the study of repro­ tary.48,49 However, in 1901 Frohlich re­ ductive cycles in animals have shown a ported a patient with a suprasellar tumor, functional connection
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Astrocytoma: a Hormone-Sensitive Tumor?
    International Journal of Molecular Sciences Review Astrocytoma: A Hormone-Sensitive Tumor? Alex Hirtz 1, Fabien Rech 1,2,Hélène Dubois-Pot-Schneider 1 and Hélène Dumond 1,* 1 Université de Lorraine, CNRS, CRAN, F-54000 Nancy, France; [email protected] (A.H.); [email protected] (F.R.); [email protected] (H.D.-P.-S.) 2 Université de Lorraine, CHRU-Nancy, Service de Neurochirurgie, F-54000 Nancy, France * Correspondence: [email protected]; Tel.: +33-372746115 Received: 29 October 2020; Accepted: 27 November 2020; Published: 30 November 2020 Abstract: Astrocytomas and, in particular, their most severe form, glioblastoma, are the most aggressive primary brain tumors and those with the poorest vital prognosis. Standard treatment only slightly improves patient survival. Therefore, new therapies are needed. Very few risk factors have been clearly identified but many epidemiological studies have reported a higher incidence in men than women with a sex ratio of 1:4. Based on these observations, it has been proposed that the neurosteroids and especially the estrogens found in higher concentrations in women’s brains could, in part, explain this difference. Estrogens can bind to nuclear or membrane receptors and potentially stimulate many different interconnected signaling pathways. The study of these receptors is even more complex since many isoforms are produced from each estrogen receptor encoding gene through alternative promoter usage or splicing, with each of them potentially having a specific role in the cell. The purpose of this review is to discuss recent data supporting the involvement of steroids during gliomagenesis and to focus on the potential neuroprotective role as well as the mechanisms of action of estrogens in gliomas.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • High-Grade Glioma/Glioblastoma Multiforme: Is There a Role for Photodynamic Therapy?
    S-31 Supplement High-Grade Glioma/Glioblastoma Multiforme: Is There a Role for Photodynamic Therapy? Presented by Harry T. Whelan, MD, Medical College of Wisconsin, Milwaukee, Wisconsin Abstract backward glance at the origins of PDT for brain tumors, In the United States, the 5-year survival rate for patients of all ages describes the clinical challenges to its use in the skull, with all types of brain tumors is approximately 20%, with the scale skewed toward even poorer survival in patients with gliomas. Al- and outlines the objectives of his phase I study for PDT though surgery and radiotherapy are primary treatment options, in children with brain cancer, the second most common surgery is rarely curative and radiotherapy has had little impact childhood cancer after leukemia. on overall survival. Predominantly studied in adults with advanced Gliomas are among the most challenging of brain high-grade gliomas, photodynamic therapy (PDT) represents tumor subtypes. The location of a benign tumor in the a paradigmatic shift in the treatment of brain tumors. With no eloquent areas of the brain could potentially render it clear standard of care for brain tumors, PDT may emerge as a po- tential alternative, although challenges regarding its clinical use inoperable, the presence of a blood–brain barrier limits remain and studies confirming its promise are necessary. JNCCN( the ability of systemically administered medications to 2012;10[Suppl 2]:S31–S34) reach the target site, and the intricate neuronal net- work makes targeted therapy challenging. Patients with high-grade gliomas (HGGs) in particular have a generally poor prognosis, and surgery is rarely curative.
    [Show full text]